For our first quarter 2026 earnings call, today, I'll review key takeaways and provide an update on our platform programs. Following my review of recent developments at INmune Bio, I will pass the ...

Hit identification and hit validation represent distinct but connected stages of early drug discovery. This article examines ...

State and local AI laws governing hiring and selection procedures are already in effect with more on the way. Employers can take ...

Key market opportunities include providing specialized training on cleaning validation, ensuring pharmaceutical production facilities meet regulatory standards, and preventing contamination risks ...

Mental health clinicians have started asking clients how they use generative artificial intelligence chatbots to support ...

Data Security Standard (DSS), issued by the PCI Security Standards Council (SSC), which establishes technical and operational ...

Greetings, and welcome to the INmune Bio's 2026 First Quarter Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this ...

Resolution of bag yield issues is projected to take until late 2026 or early 2027 before a positive effect on margin will be ...

A full Livebeam review of the verification process — how moderation works, what to expect at each step, and how customer ...

Discover how OpenAI Symphony shifts AI coding from session-based to task-oriented workflows to automate ticketing and reduce ...

On April 17, 2026, the Federal Reserve Board, the Office of the Comptroller of the Currency (OCC), and the Federal Deposit ...

UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.48244. Operator: Good day, and thank you for standing by. Welcome to the UroGen Pharma Q1 2026 Results ...